Summary: Glioblastoma, the most common and deadly primary brain tumor, shows clear sex differences in incidence, immune interactions, treatment response, and survival. New research from the University of Miami reveals a sex-specific biological mechanism in which the neurotransmitter GABA (gamma-aminobutyric acid) reprograms immune cells to protect tumors in females but not males. This discovery points to potential sex-specific immunotherapy strategies for glioblastoma and possibly other cancers that recruit similar suppressive immune cells.
Key Findings
- Distinct immune cell profiles: Male glioblastoma models and patient tumors are enriched in monocytic myeloid-derived suppressor cells (mMDSCs), while female tumors show a greater role for granulocytic MDSCs (gMDSCs), which associate with worse outcomes in women.
- GABA-driven metabolic reprogramming: In female gMDSCs, GABA signaling changes cellular metabolism and amplifies immunosuppressive functions. This effect is not observed in male MDSCs.
- Therapeutic potential: Pharmacological blockade of GABA receptors reduced tumor-promoting activity of gMDSCs and improved survival in female preclinical models, with no benefit seen in male models.
- Validation in human tissue: Tumor biopsies from female glioblastoma patients show higher levels of GABA and GABA receptors in gMDSCs compared with male samples, supporting the translational relevance of the findings.
- Broader oncology relevance: Because MDSCs are recruited by many aggressive tumors, targeting sex-specific metabolic or signaling pathways in these cells could have applications beyond glioblastoma.
Source: University of Miami
Overview
Researchers at Sylvester Comprehensive Cancer Center (University of Miami Miller School of Medicine) have identified a female-specific mechanism by which glioblastoma hijacks the immune microenvironment. The study, published in Nature Cancer and led by Defne Bayik, Ph.D., with key contributions from Asmita Pathak, Ph.D., demonstrates that GABA signaling activates a metabolic program in granulocytic myeloid-derived suppressor cells (gMDSCs) that enhances their ability to suppress T cells and shield tumors from immune attack — a pathway that appears to operate predominantly in females.
Biological sex shapes immune function at multiple levels, influencing disease susceptibility, symptom patterns, and responses to therapy. In cancer, these differences affect how tumors interact with the host immune system and how patients respond to immunotherapies. Glioblastoma incidence and mortality are higher in men, but this study shows that the underlying immune biology can differ dramatically between sexes and that these differences may be exploitable for targeted treatment.
The team focused on MDSCs, a group of immature myeloid cells that normally help restrain excessive immune activity. Tumors recruit and reprogram MDSCs into an immunosuppressive state that blocks anti-tumor T cell responses. Earlier work from the group revealed sex-skewed MDSC distributions in glioblastoma: mMDSCs dominate in males, while gMDSCs are more prominent in females and correlate with poorer outcomes in women.
In the current study, researchers tested candidate drugs and molecular pathways that could drive gMDSC activity. Several lead candidates implicated GABA-related signaling. Laboratory experiments showed that exposing gMDSCs to GABA altered their metabolism through upregulation of a transporter–L-arginine–NOS2 (nitric oxide synthase 2) axis, increasing their capacity to suppress T cells. This metabolic and functional reprogramming occurred only in female-derived gMDSCs; male MDSCs remained unresponsive to GABA.
Critically, blocking the GABA B receptor (GABBR) in female preclinical glioblastoma models reduced NOS2 levels within tumor-infiltrating gMDSCs and extended survival, while the same intervention had no measurable effect in male models. Analysis of patient tumor samples supported these results: immune cells from women with glioblastoma displayed enriched GABA transcriptional signatures and higher GABA concentrations than cells from men.
Implications for Treatment
These results argue for a more nuanced, sex-aware approach to cancer immunotherapy development. A therapy that blocks GABA signaling in gMDSCs could provide benefit specifically to female glioblastoma patients, while different strategies may be necessary to target mMDSC-driven immune suppression in males. Since MDSCs contribute to immune evasion in many tumor types, understanding sex-specific metabolic and signaling pathways in these cells may reveal broadly useful therapeutic targets.
Key Questions Answered
A: MDSCs normally act as regulators that dampen excessive immune responses. Tumors co-opt MDSCs, recruiting and reprogramming them to suppress anti-tumor T cells, creating an immunosuppressive microenvironment that enables tumor growth.
A: Female granulocytic MDSCs express higher levels of GABA receptors and respond to GABA by shifting their metabolism into an immunosuppressive state through the cationic amino acid transporter–L-arginine–NOS2 pathway. Male MDSCs, which are often monocytic, do not undergo this metabolic reprogramming in response to GABA and remain unaffected.
A: The study demonstrates that glioblastoma uses different immune mechanisms in males and females. Recognizing these differences could guide development of sex-specific therapies—such as GABA pathway inhibitors for women—rather than applying a one-size-fits-all approach in clinical trials and treatment design.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The original journal paper was reviewed in full by the editorial team.
- Additional context and clarification were added by staff for readability.
About this brain cancer research news
Author: Sandy Van
Source: Sylvester Comprehensive Cancer Center, University of Miami
Contact: Sandy Van – Sylvester Comprehensive Cancer Center
Image credit: Neuroscience News
Original Research (open access): Pathak A., Bayik D., et al. “GABA signaling activation drives glioblastoma progression in female mice through myeloid-derived suppressor cells.” Nature Cancer. DOI: 10.1038/s43018-026-01192-5
Abstract (concise)
This study identifies γ-aminobutyric acid (GABA) as a female-specific immunomodulatory driver of glioblastoma progression. GABBR signaling enhances T cell suppression by granulocytic MDSCs in female mice through upregulation of the cationic amino acid transporter–L-arginine–NOS2 pathway. GABBR activation promotes tumor growth in female preclinical models; conversely, GABBR antagonism extends survival and lowers NOS2 in tumor-infiltrating gMDSCs only in females. Immune cells from female glioblastoma patients display enriched GABA signatures and higher GABA concentrations than male counterparts, highlighting a sex-specific pathway that could be targeted in cancer immunotherapy.